Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines

Executive Summary

Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.


Related Content

How To Get Ahead In The Trendy World Of Immuno-Oncology
BioNTech's Sean Marett Explains Genentech Deal Rationale
Genentech's Associate Oncology Director Talks Cancer Vaccine Challenges
Freshly Financed CureVac Seeks Partner To Keep Up In mRNA
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Sanofi Hopes BioNTech Pact Can Help Reboot Cancer Prospects
Genmab and BioNTech to take BAbs all the way in crowded immuno-oncology
Deal Watch: U.S. Pharmas Look To Europe For Partners


Related Companies